3M Aldara submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
3M submits sNDA for use of its topical immune response modifier Aldara (imiquimod cream, 5%) for superficial basal cell carcinoma. The submission is based on two six-week, double-blind, placebo-controlled studies in 724 patients. The studies found dosing five times a week to be the optimal regimen, with a histological clearance rate of 82% vs. 3% for placebo. Aldara could also be cleared for another indication in 2004; 3M submitted an sNDA May 5 for actinic keratosis (1Pharmaceutical Approvals Monthly June 1, 2003, p. 15)...
You may also be interested in...
3M Submits Aldara For Actinic Keratosis, Plans Carcinoma Filing Mid-Year
3M could gain two new indications for its topical immune response modifier Aldara in 2004, with a recent submission for actinic keratosis and a filing for basal cell carcinoma planned for this summer.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.